Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dogwood Therapeutics (DWTX)
NASDAQ:DWTX
RESEARCH TOOLSreports
Holding DWTX?
Track your performance easily
DWTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.62 - $23.50
Previous Close$2.68
Volume30.63K
Average Volume (3M)105.86K
Market Cap
$3.77M
Enterprise Value$1.57M
Total Cash (Recent Filing)$2.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.23
Next Earnings
Mar 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.87
Shares Outstanding1,332,178
10 Day Avg. Volume114,128
30 Day Avg. Volume105,862
Standard Deviation0.36
R-Squared0.04
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)3.42
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
$15.00Price Target Upside437.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Dogwood Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial StabilityCKLS has agreed to loan $19.5M to the newly created Dogwood Therapeutics, potentially extending the company's cash runway into 2026.
Regulatory AdvancementsHalneuron was granted Fast-Track Designation by the FDA for P2b development in chemotherapy-induced neuropathic pain, where there are currently no approved treatments.
Strategic PartnershipsThe merger with Wex Pharmaceuticals introduces Halneuron, a promising non-opioid painkiller that has shown positive results in clinical trials, to the company's product pipeline.
Bears Say
Financial PerformanceDogwood Therapeutics reported a net loss of $2.3 million and ended the period with $2 million in cash on the balance sheet.
Ownership DilutionCurrent Virios shareholders are expected to account for approximately 6% of the new entity, suggesting a significant dilution of ownership.
Valuation ConcernsVirios was facing a capital constraint, which was reflected in a distressed valuation.
---
Ownership Overview
63.00%
Insiders
― Other Institutional Investors
37.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DWTX FAQ
What was Dogwood Therapeutics’s price range in the past 12 months?
Dogwood Therapeutics lowest stock price was $1.62 and its highest was $23.50 in the past 12 months.
What is Dogwood Therapeutics’s market cap?
Currently, no data Available
When is Dogwood Therapeutics’s upcoming earnings report date?
Dogwood Therapeutics’s upcoming earnings report date is Mar 13, 2025 which is in 105 days.
How were Dogwood Therapeutics’s earnings last quarter?
Currently, no data Available
Is Dogwood Therapeutics overvalued?
According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued.
Does Dogwood Therapeutics pay dividends?
Dogwood Therapeutics does not currently pay dividends.
What is Dogwood Therapeutics’s EPS estimate?
Dogwood Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dogwood Therapeutics have?
Dogwood Therapeutics has 1,332,178 shares outstanding.
What happened to Dogwood Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Dogwood Therapeutics?
Currently, no hedge funds are holding shares in DWTX
---
Dogwood Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.59%
12-Months-Change
Fundamentals
Return on Equity
-119.56%
Trailing 12-Months
Asset Growth
-30.24%
Trailing 12-Months
Company Description
Dogwood Therapeutics
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia.
---
DWTX Earnings Call
Q3 2024
0:00 / 0:00
---
DWTX Stock 12 Month Forecast
Average Price Target
$15.00
▲(437.63% Upside)
Technical Analysis
Best Analysts Covering DWTX
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-48.82%
reiterated a buy rating 21 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -48.82% per trade.
---